reports
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Pr...
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of , a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and healt...
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adul...
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in projecting a significant rise in obstructive sleep apnea (OS...
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awar...
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its nasal cradle mask won two prestigious : Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company als...
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 20...
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue incre...
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location: •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / ...
ResMed Inc: 1 director
A director at ResMed Inc sold 2,000 shares at 247.320USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Resmed Champions Sleep Health as The Official Sleep Partner of The Qat...
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans’ dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will b...
Resmed Acquires VirtuOx
Resmed Acquires VirtuOx Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more a...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 202...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin ...
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Resmed Names Salli Schwartz as Chief Investor Relations Officer Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairm...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, ...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, ™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified,...
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location: •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PD...
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%. SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in , demonstrating that CPAP t...
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Techn...
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 year...
ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling w...
ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships 7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.Women report fewer quality sleep nights and more difficulties falling asleep than men. SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), a global health technology lead...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 20...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025 Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2024. Second Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis Gross ...
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 20...
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025 SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:• Date:Thursday, January 30, 2025• Time:1:30 p....
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthca...
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay ...
ResMed Announces Participation in the UBS Global Healthcare Conference
ResMed Announces Participation in the UBS Global Healthcare Conference SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visit...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.